Ribavirin Aerosol

American Hospital Formulatory Service, American Society of Hospital Pharmacists (ASHP). (1988). Drug Information for 1988, 8(18): 383–389.

Arnold S.D. , and Buchanan R.M. (1991). Exposure to ribavirin aerosol. Applied Occupational and Environmental Hygiene, 6(4), 271–279.

Atmar R. , Englund J. , and Hamill H. (1992). Complications of measles during pregnancy. Clinical Infectious Disease, 14, 224.

Boiano J.M. , and Dietchman S. (November, 1988). Ribavirin Monitoring Survey and Health Hazard Evaluation Interim Report. Cincinnati, OH: National Institute of Occupational Health and Safety, HETA 88–120.

Bradley J.S. , Connor J.D. , and Compogiannis L.S. (1990). Exposure of health care workers to ribavirin during therapy for respiratory syncytial virus. Antimicrobial Agents and Chemotherapy, 34(4), 668–670.

Canadian Pediatric Society. (1991). Position statement: Ribavirin: Is there a risk to hospital personnel? Canadian Medical Association Journal, 144(3), 285–286.

Cefaratt J.L. , and Steinberg E.A. (1992). An alternative method for delivery of ribavirin to nonventilated pediatric patients. Respiratory Care, 37(8), 877–881.

Charney W. , Cordery K.J. , Kraemer R. , and Wugofski L. (1990). Engineering and adminstrative controls to contain aerosolized ribavirin: Results of simulation and application to one patient. Respiratory Care, 35(11), 1042–1048.

Cohen B.A. , and Brady M. (1992). Practices surrounding ribavirin administration. Pediatric Nursing, 18(3), 253–257.

Decker J. (1992a). Aerosolized ribavirin—Exposures and controls (NIOSH health hazard evaluation case report). Applied and Occupational Environmental Hygiene, 7(3), 152–155.

Decker J. (1992b). Evaluation of respirator performance against aerosolized ribavirin in a health care setting (NIOSH health hazard evaluation case report). Applied and Occupational Environmental Hygiene, 7(4), 216–217.

Demers R.R. , Parker J. , Frankel L.R. , and Smith D.W. (1986). Administration of ribavirin to neonatal and pediatric patients during mechanical ventilation. Respiratory Care, 31, 1188–1196.

Englund J.A. , Piedra P.A. , Jefferson L.S. , Wilson S.Z. , Taber L.H. , and Gilbert B.E. (1990). High-dose, short duration aerosol therapy in children with suspected respiratory syncytial virus infection. Journal of Pediatrics, 117, 313–320.

Ferm V.H. , Wilhite C. , and Kilham L. (1978). Teratogenic effects of ribavirin on hamster and rat embryos. Teratology, 17, 93–102.

Gallagher R. , Givan N. , and Hazelden K. (March, 1977). Teratogenicity Testing in Baboons of Vierazole. Costa Mesa, CA: ICN Pharmaceuticals.

Gladu J.M. , and Ecobichon D.J. (1989). Evaluation of exposure of health care personnel to ribavirin. Journal of Toxicology and Environmental Health, 28, 1–12.

Harrison R. , Bellows J. , and Rempel D. (1988). Assessing exposures of health care personnel to aerosols of ribavirin. Morbidity and Mortality Weekly Report, 37(36), 560–563.

Hillyard I.W. (1980). The preclinical toxicology and safety of ribavirin. In: Smith R.A. , and Kirkpatrick W. (Eds.) Ribavirin: A Broad Spectrum Antiviral Agent. New York, NY: Academic Press, pp. 59–71.

Johnson E.M. (1990). The effects of ribavirin on development and reproduction: a critical review of published and unpublished studies on experimental animals. Journal of the American College of Toxicology, 9, 551–561.

Kacmarek R.M. , and Kratohvil J. (1992). Evaluation of a double-enclosure double-vacuum unit scavenging system for ribavirin administration. Respiratory Care, 37(8), 877–881.

Kilham L. , and Ferm V.H. (1977). Congenital abnormalities induced in hamster embryos with ribavirin. Science, 195, 413–414.

Knight V. , Gilbert B.E. , and Divine G.W. (1988). Estimating the dosage of ribavirin aerosol according to age and other variables. Journal of Infectious Diseases, 158(2), 443–448.

Knight V. (1989, June). Methods for the Safe and Effective Administration of Aerosolized Ribavirin. Paper presented at NIOSH/CDC Public Meeting, Atlanta, GA.

Kochar D.M. , Penner J.D. , and Knudsen T.B. (1980). Embryotoxic, teratogenic and metabolic effects of ribavirin in mice. Teratology and Applied Pharmacology, 52, 99–112.

Lenhart S.W. , and Decker J.A. (1991). Health Hazard Evaluation Report. Cincinnati, OH: National Institute for Occupational Safety and Health, HETA 90-155-2169.

Matlock D. , Buchan R.M. , and Tilery M. (1991). A local exhaust ventilation system to reduce airborne ribavirin concentrations. American Industrial Hygiene Association Journal, 52(10), 428–432.

NIOSH. (1989). NIOSH Method 5027. NIOSH Manual of Analytical Methods. Cincinnati, Ohio: NIOSH.

Outwater K.M. , Messer C. , and Peterson M.B. (1988). Ribavirin administration to infant receiving mechanical ventilation. American Journal of Diseases of Children, 1423, 512–515.

Rodriguez W.J. , DangBui R.H. , Connor J.D. , Kim H.W. , Brandt C.D. , Parrot R.H. , Burch B. , and Mace J. (1987). Environmental exposure of primary care personnel to ribavirin aerosol when supervising treatment of infants with respiratory syncytial virus infections. Antimicrobial Agents and Chemotherapy, 31(7), 1143–1146.

Torres A. , Krilov L.R. , Jacobson J.M. , Kelly K.J. , and Havens PL. (1991). Reduced environmental exposure to aerosolized ribavirin using a simple containment system. Pediatric Infectious Diseases Journal, 10(3), 217–221.

U.S. Environmental Protection Agency. (1986). Guidelines for the health assessment of suspect developmental toxicants. Federal Register, 51(185), 34028–34040.

Waskin H. (1991). Toxicology of antimicrobial aerosols: A review of aerosolized ribavirin and pentamidine. Respiratory Care, 36, 1026–1036.